Pexidartinib in patients with tenosynovial giant cell tumor: a plain language summary of the final results from ENLIVEN

William Tap

Open source

DOI
10.1080/14796694.2026.2663959
Published
2026-05-14
Container
Future Oncology
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2663959,
  title = {Pexidartinib in patients with tenosynovial giant cell tumor: a plain language summary of the final results from ENLIVEN},
  author = {William Tap},
  year = {2026},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2026.2663959},
  url = {https://doi.org/10.1080/14796694.2026.2663959}
}

RIS

TY  - JOUR
TI  - Pexidartinib in patients with tenosynovial giant cell tumor: a plain language summary of the final results from ENLIVEN
AU  - William Tap
PY  - 2026
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2663959
UR  - https://doi.org/10.1080/14796694.2026.2663959
ER  - 

APA

Tap, W. (2026). Pexidartinib in patients with tenosynovial giant cell tumor: a plain language summary of the final results from ENLIVEN. Future Oncology. https://doi.org/10.1080/14796694.2026.2663959

Source records